Bill Meagher

Bill Meagher's focus with The Deal is on small and microcap equity finance, healthcare and biotechnology, PIPEs, and companies going public. His work has appeared in newspapers and magazines throughout California as well as on PBS, “60 Minutes,” ABC News and CNBC. Meagher has also written video scripts and produced national events for a non-profit educational organization and ghost written two books.

Recent Articles By The Author

'Pharma Bro' Shkreli is Jailed After Judge Revokes His $5 Million Bond

'Pharma Bro' Shkreli is Jailed After Judge Revokes His $5 Million Bond

Despite pleading with his judge through a letter, Martin Shkreli had his $5 million bail revoked and will sit in jail while he awaits sentencing on securities fraud conviction.

Herpes Vaccine Biotech Catches Flak Over Sketchy Offshore Trials

Herpes Vaccine Biotech Catches Flak Over Sketchy Offshore Trials

Rational Vaccines lost one of its founders to cancer in June. The other founder is an Oscar winner with no medical background, and the company just received $7 million in capital from investors that include venture guru Peter Thiel. Rational is also under investigation by West Indies medical authorities for an unauthorized drug trial and having medical ethics concerns.

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Following the lead of more than 400 CEOs across the nation, life science executives penned an open letter to President Trump urging him to step back from his DACA decision.

Healthcare Management Stocks Look Too Pricey for Activists

Healthcare Management Stocks Look Too Pricey for Activists

Though plenty of activist investors still hold positions in healthcare management companies, just as many have traded out of the stocks following merger deals gone south.

New Studies Cast Doubt on FDA Approval Process

New Studies Cast Doubt on FDA Approval Process

A pair of new studies regarding how drugs and medical devices gain approval from the FDA have pointed out that those trials may not be of the highest quality.